172@29@17@137!~!172@29@0@53!~!|news|business|markets|modi-2-0-five-stocks-more-than-doubled-while-20-rose-more-than-50-in-first-year-of-modis-second-stint-5336561.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Upcoming Webinar: Analyse the security landscape of digital payments at 11 am on October 20. Register now!
Last Updated : May 30, 2020 01:38 PM IST | Source: Moneycontrol.com

Modi 2.0: Five stocks more than doubled while 20 rose over 50% in first year of Modi's second stint

There are 20 stocks that rallied more than 50 percent since May 30, 2019 in the S&P BSE 500 index that include names like Dhanuka Agritech, Granules India, AstraZeneca Pharma, etc. among others.


Investors might have lost about Rs 27 lakh crore in terms of market capitalisation in the first year of Modi 2.0, but five stocks turned multibaggers and 20 stocks rose more than 50 percent in the first year of the Modi government's second stint at the Centre.

The average market capitalisation of the BSE-listed companies fell from Rs 154.43 lakh crore as on May 30 2019 to Rs 127.06 lakh crore as on May 29, 2020.

Close

The Narendra Modi-led government marks the first anniversary of its second term today. The market did hit a record high back in January but the course changed as bears took control of D-Street pushing the index towards crucial support levels.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

There are as many as five stocks in the S&P BSE 500 index which turned wealth creators in the last 12 months including names like Abbott India, Navin Fluorine, Alkyl Amines Chemicals, GMM Pfaudler, and Adani Green Energy Ltd.


BSE 500 1 year



Note: The above table is for reference and not buy or sell recommendation


There are 20 stocks that rallied more than 50 percent since May 30, 2019 in the S&P BSE 500 index that include names like Dhanuka Agritech, Granules India, AstraZeneca Pharma, Ipca Laboratories, Dixon Technologies, and ICICI Securities, etc. among others.

The last year turned out to be a volatile year for Indian markets. Although optimism of the second term of the Modi government also meant pro-growth reforms which helped benchmark indices climb the wall of worries as growth took a hit, along with rising inflation.

modi_2.0

Global cues remain muted as the equity investors across the world turned risk-averse largely on account of the US-China trade war, as well as outbreak of COVID-19 which resulted in  shutdown of economic activity not just for India but other countries across the globe.

The reforms initiated by the Modi-led government in its second term are pro-growth and bold decisions which the nation has seen in the last 70 years – pushing the nation towards ‘Atma Nirbhar Bharat’.

However, the growth factor might come with a lag, and implementation of the said reforms in mining, agriculture, ease of doing business, defense, as well as land.

“We have to factor in the series of unexpected events (both global and local) in the background of which these reform measures have been taken boldly without worrying about the political fallouts,” Deepak Jasani- Head of Retail Research, HDFC Securities told Moneycontrol.

“PM Modi needs to continue promoting a good second level of able ministers with sufficient powers within defined limits. While a lot of reform measures have already been announced, the implementation part is lagging due to legacy process issues and reluctance of babudom in coming onboard. Also, the judiciary (and lawyers) have so far not changed sufficiently with the times,” he said.

What to watch out for?

The Indian market has fallen over 23 percent since May 30. And, the majority of the fall happened in the last 3-4 months thanks to the outbreak of COVID-19 which pushed Sensex and Nifty in a bear market, but small & midcaps have been in bear markets for the past 2 years.

As many as 54 percent of the experts polled by Moneycontrol feel that the S&P BSE Sensex could trade in the range of 35,000-40,000 which translates into an upside of 14-30 percent from May 26 closing level of 30,609.

Also Read - One year of Modi 2.0: Analysts see Sensex in 35000-40000 range in a year

About 31 percent of the analyst feel that the markets are likely to remain flat and move in a range of 30,000-35,000 in the next one year.

About 7 percent feel that we could see a record high above 43,000 while the remaining 8 percent are bearish and see the index trading below 30,000 in the next one year.

In terms of earnings, almost 77 percent of the analysts polled by Moneycontrol are of the view that earnings are unlikely to recover anytime soon while the rest 23 percent are of the view that there is a chance of recovery in earnings in the next 1 year.

The 4QFY20 earnings season has brought to the fore the challenging terrain ahead with multiple headwinds and moving parts. The adverse economic impact of COVID-19 is expected to wipe out FY21E earnings growth, suggest experts.

“The two months of economic lockdown has taken a toll on corporate balance sheets even as underlying demand has suffered. The management commentaries suggest more volatility and disruption in earnings ahead with several Nifty companies seeing fresh double-digit EPS cuts for FY21E,” Ajay Menon, CEO, Broking and Distribution, Motilal Oswal Financial Services Ltd told Moneycontrol.

“However, most company management have stressed the unique and unprecedented nature of the crisis, resulting in difficulty in providing guidance/predictions. So far, we are building in Nifty EPS decline of 2.4% for FY20 to INR472 and growth of +2.7% for FY21E to INR485,” he said.

Experts feel that FY21 would be a flat year in terms of earnings growth for Indian corporate. Post the double-digit y-o-y decline in the first half of FY21, analysts see a recovery in the second half.

Modi 2.0: Track all coverage here

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on May 30, 2020 01:36 pm
Sections